Article ID Journal Published Year Pages File Type
3339729 Allergologia et Immunopathologia 2014 7 Pages PDF
Abstract
After treatment switch from low-dose ICS to montelukast, asthma control was maintained in the majority of patients during the 12-week observation period. Sputum eosinophilia or BHR before the treatment switch was exacerbation risk factor.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Immunology
Preview
Evaluation of step-down therapy from an inhaled steroid to montelukast in childhood asthma
Authors
, , ,